Marshall Wace
ALXO icon

Marshall Wace’s ALX Oncology ALXO Stock Holding History

Marshall Wace’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.51M Buy
3,757,216
+3,730,840
+14,145% +$7.11M 0.01% 1105
2025
Q4 		$29.8K Sell
26,376
-13,207
-33% -$20K ﹤0.01% 2812
2025
Q3 		$72.4K Sell
39,583
-66,697
-63% -$57.8K ﹤0.01% 2695
2025
Q2 		$44.6K Sell
106,280
-164,917
-61% -$83.2K ﹤0.01% 2604
2025
Q1 		$168K Buy
+271,197
New +$326K ﹤0.01% 2435
2024
Q4 		– Sell
-160,059
Closed -$291K – 2550
2024
Q3 		$291K Sell
160,059
-475,620
-75% -$1.77M ﹤0.01% 2159
2024
Q2 		$3.83M Buy
635,679
+514,133
+423% +$6.32M 0.01% 1114
2024
Q1 		$1.36M Buy
121,546
+109,977
+951% +$1.54M ﹤0.01% 1529
2023
Q4 		$172K Buy
+11,569
New +$110K ﹤0.01% 2000
2023
Q2 		– Sell
-17,583
Closed -$79.5K – 2425
2023
Q1 		$79.5K Buy
+17,583
New +$133K ﹤0.01% 2516
2022
Q4 		– Sell
-24,177
Closed -$231K – 2902
2022
Q3 		$231K Buy
+24,177
New +$282K ﹤0.01% 3044
2022
Q1 		– Sell
-106,875
Closed -$2.29M – 3302
2021
Q4 		$2.29M Buy
+106,875
New +$4.61M ﹤0.01% 1954
2021
Q3 		– Sell
-18,021
Closed -$985K – 2980
2021
Q2 		$985K Buy
+18,021
New +$1.08M ﹤0.01% 1815

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Marshall Wace's ALXO Position: Q1 2026 in Review

Marshall Wace increased its ALX Oncology (ALXO) stake by 14,145% in Q1 2026, buying an estimated $7.11M and bringing the position to 3,757,216 shares worth $7.51M. The position accounts for 0.01% of the portfolio, ranked #1105.

Marshall Wace first reported a position in ALXO in Q2 2021 and has held it in 13 quarters since. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Marshall Wace held 3,757,216 shares of ALX Oncology worth $7.51M as of Q1 2026.
  • Marshall Wace bought 3,730,840 ALX Oncology shares in Q1 2026, an estimated $7.11M.
  • ALX Oncology made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1105 holding.
  • Marshall Wace first reported a position in ALX Oncology in Q2 2021 and has held it in 13 quarters since.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.